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Weight restoration is considered a principal outcome for treatment of Anorexia Nervosa (AN) due to the significant
physiological disturbances resultant from acute states of malnutrition. Treatment outcomes for populations with AN
are relatively poor, with increasing evidence suggesting that weight restoration alone is insufficient for long-term
recovery. Research aimed at understanding the psychological sequaele of AN, in particular during weight restoration,
nevertheless remain scarce. This systematic review aimed to evaluate existing research regarding anxiety symptoms
during treatment for AN, and the relationship of anxiety symptomology and weight restoration. Twelve articles were
identified from a systematic search of three electronic databases (PsycINFO, MEDLINE, and Web of Science), and were
eligible for inclusion. Study methodology, results and quality were reviewed. Results regarding change in anxiety
symptomology were inconsistent, though evidence did not support a relationship between anxiety change and weight
restoration. Reasons for these inconsistencies and limitations of included studies were reviewed. Further research is
warranted to elucidate the role of anxiety in AN and its implications for treatment and longer-term outcome.
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Anorexia Nervosa (AN) is a severe ego-syntonic psychi-
atric illness [1] characterized by a refusal to maintain a
minimally normal body weight and an intense fear of
gaining weight or becoming fat (DSM-5) [2]. Severe mal-
nutrition associated with AN results in a number of
deleterious physiological outcomes [3,4] and moreover,
is associated with AN having the highest mortality rate
of any psychiatric disorder [1,5,6], with standardized mor-
tality ratios (i.e., the ratio of observed to expected deaths)
estimated at approximately 5.86 to 8.85 [7,8]. Inpatient ad-
missions aimed at correcting the biological sequelae of
malnutrition are thus indicated for individuals with AN at
imminent risk of severe medical compromise [9,10].
At present treatment outcomes for individuals with
AN is relatively poor with longitudinal research demon-
strating that high dropout rates [11-13], high rates of re-
admission [14,15], and low rates of long-term holistic
recovery [5,7] should be considered normative [16]. Fur-
thermore, evidence suggests that individuals who are
discharged or dropout from inpatient wards prior to
achieving weight normalization are more likely to be* Correspondence: skez2915@uni.sydney.edu.au
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unless otherwise stated.re-hospitalised and have poorer treatment outcomes in
the long-term [17,18]. Importantly, low body mass
index (an indicator for those individuals most in need
of nutritional rehabilitation) at referral has been associ-
ated with poorer treatment outcome and prognosis
[19]. While weight restoration is unquestionably a fun-
damental clinical aspect of AN that needs to be tar-
geted in treatment interventions, there are increasing
suggestions that changes in weight restoration alone are
insufficient for long-term recovery [8,20,21]. Thus, consid-
eration of additional factors that may be associated with
and contribute to this treatment profile is necessitated.
Clinical consensus accepts that psychological variables
are affected by the acute stage of malnutrition. That is,
starvation can result in psychological complications, in-
cluding effects on mood and cognitive functioning [22,23].
Less is known, however, about the progression of psycho-
logical variables during the different stages of AN and
their role in the maintenance of anorectic symptomology.
Questions have repetitively been raised as to whether psy-
chological symptoms should be regarded solely as compli-
cations of malnutrition, or whether they represent unique
psychiatric features that need to be considered independ-
ently, and/or whether psychiatric comorbidity needs to beral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that core behavioral, attitudinal, and emotional distur-
bances [24,25] may persist after weight normalization and
that core psychological difficulties do not automatically re-
solve following weight restoration in patients with AN
[26-28], research remains limited.
A previous review addressing the aforementioned
question considered both depressive and anxiety symp-
tomology [29]. This review included 7 studies represent-
ing heterogeneous methodology and reporting largely
contradictory findings, rendering a conclusive result im-
practicable [29]. There have been some theoretical sug-
gestions that depressive symptomology in AN results in
response to prolonged illness and symptom chronicity
[30], whereas anxiety symptomology may increase vul-
nerability to eating disorder pathology [31]. Consistent
with these suggestions, Hughes [32] in a comprehensive
review of comorbid depression and anxiety in childhood
and adolescent AN found that while anxiety symptoms
tended to pre-date AN onset and persist following re-
covery, depression was likely to onset after AN and
abate following recovery. As such, the current study
chose to focus exclusively on anxiety symptomology in
order to elucidate possible findings.
Focus on anxiety is further implicated by recent litera-
ture indicating high rates of psychiatric comorbidity
between anxiety disorders and AN [33], marked sympto-
mological overlap [28,34], evidence purporting the anxio-
lytic effects of AN behaviours [35], and more recent
developments indicating a shared neurobiological profile
[36-38]. Furthermore, there is some evidence to suggest
that experiences of anxiety in populations of individuals
with AN may be an indicator of poor treatment outcome
[31]. In fact, Zerwas et al. [39] found that trait anxiety was
a negative prognostic factor independently associated with
AN recovery, and Thornton et al. [40] found that individ-
uals with comorbid AN and Generalised Anxiety Disorder
(GAD) diagnoses attained significantly lower BMI’s than
individuals with AN only. Despite increasing evidence
documenting the functional interplay between AN and
anxiety, and suggestions pointing to the utility of under-
standing anxiety symptomology for efficacious treatment
of AN [41], research remains limited.
Consequently, the current study sought to conduct a
systematic review of research examining the relationship
between anxiety symptomology and weight restoration in
individuals with AN. Despite increasing evidence impli-
cating the significance of anxiety symptomology in AN,
the complex relationship of biological and psychological
factors resulting in poor treatment outcomes appears to
be poorly understood. This review aims to specifically
clarify the expression of anxiety symptoms during treat-
ment, and to determine the nature of the relationship be-
tween anxiety and weight normalization in AN patients.Method
Search procedure and selection criteria
A comprehensive search of three electronic databases
(PsycINFO, MEDLINE, and Web of Science) was con-
ducted to identify relevant studies published before July
2014. Key search terms were (anorexia nervosa OR an-
orexia) AND (weight gain OR refeeding OR nutritional
rehabilitation) AND (anxiety OR psychological stress OR
distress OR fear OR psychological impact). This search
identified 878 records, of which 150 were duplicates. Of
the 728 records, a review of the titles and abstracts dem-
onstrated that 642 did not meet inclusion criteria; these
were omitted. A second author independently screened
10% of the titles and abstracts to control for selection
bias, which demonstrated overall agreement in the selec-
tion of relevant articles chosen for review. The remaining
86 full-text articles were assessed for eligibility.
To be eligible for inclusion, studies were required to
have (a) examined a population with AN, (b) utilized a
standardized measure of anxiety, (c) assessed change in
weight status, (d) presented original data, and (e) been
published in English in a peer-reviewed journal. To allow
for comprehensive inclusion of studies from the available
literature no restrictions were placed on (a) study design,
(b) examination of the relationship between change in anx-
iety and change in weight status, and (c) criteria of age or
gender of participants. Studies were excluded, however, if
they did not explicitly examine an AN population (i.e., they
included Eating Disorder Not Otherwise Specified or
Bulimia Nervosa and did not report data specific to AN),
or did not examine the primary outcomes of interest (e.g.,
measured depression only). Overall, 12 articles reached the
standards stipulated by the inclusion and exclusion criteria.
Figure 1 presents a flow diagram of the selection process.
Data extraction
Data information collected included study design, demo-
graphic characteristics (age, gender, baseline BMI), diag-
nostic status (diagnostic criteria applied, AN subtype
specification, medication use) and details of outcome
measures (anxiety and weight measures, time point for
measurements). Importantly, while studies documented a
range of psychopathological variables (e.g., depression,
motivation for change, obsessive compulsive disorder)
and/or neuropsychological variables (e.g., executive func-
tioning, processing speed) only data pertaining to anxiety
was collected for the purpose of this systematic review.
Further information pertaining to statistical analysis proce-
dures and correlational outcome data specifically (i.e., rela-
tionship between anxiety and weight) was also extracted.
Quality assessment
Study quality was assessed using a modified version of
the original Quality Index by Downs and Black [42]. The
Figure 1 Flow-diagram of selection process.
Kezelman et al. Journal of Eating Disorders  (2015) 3:7 Page 3 of 15Quality Index has been shown to be a valid and reliable
tool for assessing methodological quality of epidemio-
logic and health research [42,43]. While the original tool
was designed for systematic assessment of randomized
and non-randomized studies of health care interven-
tions, Ferro and Speechley [44], in their systematic re-
view in the health science field, amended the tool to
exclude items related specifically to interventions. As
such, quality items assessing randomization, blinding,
withdrawals and dropouts, and intervention integrity
were excluded. As the current systematic review does
not involve assessment of intervention studies, this
modified Quality Index was deemed appropriate. The
amended version (see Appendix 1) consists of 15 items
scored dichotomously as 0 (No/Unable to determine) or
1 (Yes) resulting in three subscales; reporting (0 – 7), ex-
ternal validity (0 – 3), and internal validity (0 – 4), witha single item assessing study power. The maximum total
score is 15, with higher scores indicated greater meth-
odological quality.Results
Twelve articles were included in this systematic review.
Studies were conducted in a number of different countries
including France (n = 3), Italy (n = 2), United Kingdom
(n = 2). United States of America (n = 2), Spain, Israel,
and Norway. The majority of studies employed longitu-
dinal designs (n = 6), with five studies utilizing a combin-
ation of cross-sectional and longitudinal data, and one
study using cross-sectional data only [45]. The age of par-
ticipants ranged from 14.4 to 29.86 years old. Tables 1
and 2 present the study characteristics and outcome data
for those studies that included direct assessment of the
Table 1 Study characteristics for studies assessing the relationship between anxiety and weight
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et al. [56]
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Note. Ax: Admission; Dx: Discharge; FU: Follow-up; MMPW; Mean Matched Population Weight. NG: Nasogastric Tube Feeding. CBT: Cognitive Behavioural Therapy. AN-R: Anorexia Nervosa – Restrictive Subtype; AN-B/P:
Anorexia Nervosa – Binge/Purging Subtype; BN: Bulimia Nervosa; s-AN: Subclinical AN; s-AN-WA: Subclinical Anorexia Nervosa without amenorrhea; s-AN-WU: Subclinical Anorexia Nervosa without weight criterion.
HARS: Hamilton Anxiety Rating Scale [63]; STAI: State-Trait Anxiety Inventory [61]. BMI: Body Mass Index. X: Information not reported; NR: Statistic not reported; ns: Non-significant N/A: Not applicable.
*Significant at p < 0.05.
aFollow-up measurement timepoint not included in current review. bDaily caloric intake not specified . cAll participants female unless otherwise indicated. dNil significant differences between patients on medication/













Table 2 Study characteristics for studies that did not directly assess the relationship between anxiety and weight







































HARS 15.9 (1.9) F = 25.3*
T2: 1 month 18.3 (1.7)*

































24.5%g STAI-Y 15.5 (1.4)
T2: Dx AN-B/P
(24.5)
- State 18.4 (0.8)* t = 1.5
T3: 9 months
post Dxa




M of 36 days
post Ax
x CRT Inpatient &
Outpatient
20 x x x STAI 16.81 (1.63)
T1 (Outpatient:
M of 13 months
post Ax
- State 17.73 (1.39)* t = 1.01










x STAI 15.03 (0.71) NR*
T2: After 1 week - State 15.02 (0.78)
T3: After 12 weeks
of therapy

























Ax – nil STAI 15.5 (0.3) NR (ns)
Dx – 33.3%gh State 19.5 (0.4)*
T2: Dxb Trait x
























x Inpatient 15.5 16 x As
previous


































Note. Ax: Admission; Dx: Discharge; FU: Follow-up. CRT: Cognitive Remediation Therapy; CBT: Cognitive Behaviour Therapy; SSRI: Selective Serotonin Reuptake Inhibitor. AN-R: Anorexia Nervosa – Restrictive Subtype;
AN-B/P: Anorexia Nervosa – Binge/Purging Subtype. HARS: Hamilton Anxiety Rating Scale [63]; STAI-Y: STAI Child and Adolescent Version [62]; STAI: State-Trait Anxiety Inventory [61]; SCARED: Screen for Child Anxiety-
Related Emotional Disorders [64]. BMI: Body Mass Index. X: Information not reported; NR: Statistic not reported; ns: Non-significant N/A: Not applicable.
*Significant at p < 0.05.
aFollow-up measurement not included in current review. bDischarge defined by achievement and maintenance of desired weight for at least two consecutive weeks. cShort-term weight restored measurements were
obtained from the original sample of underweight patients within one month after achieving weight restoration. Long-term weight restored sample refers to individuals who maintained weight restoration for a period
of 6 months to 10 years. dDaily caloric intake not specified. eAll participants female unless otherwise indicated. fNil significant differences between patients on medication/not on medication unless otherwise indicated.
gNo specification of type of pharmacological intervention provided. h% relates to portion of participants retained at discharge (50% of original sample) on medication. iAntidepressant or anxiolytic medication. jWeight
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and those that did not (n = 7).
Diagnostic criteria
Nine studies specified that participants were assessed ac-
cording to diagnostic criteria for AN prior to study com-
mencement; three studies did not specify psychiatric
diagnostic criteria [46-48]. Perez et al. [48] specified ad-
mission criteria in regard to medical presentation (severe
bradycardia, orthostatic hypotension, electrolyte abnor-
malities, inability to maintain weight and hypothermia)
rather than applying psychological criteria. Of the nine
studies utilizing specific diagnostic criteria, seven studies
applied DSM-IV or DSM-IV-TR criteria [49], one study
[45] applied DSM-III-R criteria [50], and one study uti-
lized both DSM-III-R and DSM-IV criteria [51]. These ap-
plications represent appropriate use of diagnostic manuals
that were available at the time of study publication.
In addition to diagnostic criteria, subtype specifica-
tions were documented in ten studies. Percentage of
total sample was documented for each subtype, such
that the percentage of participants with AN Restrictive
Subtype ranged from 45 to 100%, while participants with
AN Binge/Purging Subtype were less represented with
percentages ranging from 24.5 – 55%. Additional sub-
types were stipulated in one study [52], which consid-
ered two types of atypical/subclinical anorexia nervosa
presentations where all diagnostic criteria were met except
underweight status or amenorrhea. Notably, these subtype
specifications may no longer be applicable as a result of
the introduction of DSM-5 [2] that allows for greater vari-
ability in weight status at presentation accounted for by a
severity specifier.
Participant sample
Eight studies’ clinical samples were inpatient populations
only, two studies assessed an outpatient population only
[51,52], and two studies [45,46] assessed participants
from both inpatient and outpatient units. The number
of participants varied across the studies with baseline
samples ranging from 11 to103 (M = 47). Half the stud-
ies assessed adult populations, while half the studies
assessed adolescent populations. Importantly, only two
studies identified the inclusion of male participants
[53,54] with those male participants representing only
2% and 5% of the total sample, respectively. Five of the
included studies utilized a non-eating disordered control
group.
Weight measurements
All studies collected objective measurements of weight
and height, with 11 studies reporting Body Mass Indices
[BMI = weight (kg)/height (m2)] and one study reporting
percentage of ideal body weight [45]. Baseline weightmeasurements for clinical samples were consistent with
DSM-IV [49] diagnostic indications of anorexia nervosa
(i.e., BMI <17.5) with average baseline BMI ranging from
13.84 to 17.37 (M = 15.61). Pollice et al. [45] reported
that those participants in the underweight anorexia ner-
vosa group, consistent with diagnostic criterion, were on
average at 72% of the average recommended body
weight for their height according to the Metropolitan
Life Insurance Tables [55]. Some studies provided de-
tailed procedures for collection of weight measurements,
for example Mattar et al. [56] who indicated that adoles-
cents were weighed wearing light clothing and were
subsequently categorized according to Cole’s index of
thinness [57], while the majority of studies simply stated
that measurements were taken at session commencement
or did not report specific measurement procedures.
Of the five studies including control populations, three
studies [47,48,54] reported baseline BMI status, which
fell within healthy parameters ranging from 19.4 to
21.82 (M = 20.64). Pollice et al. [45] documented that on
average control participants were at 104% of the average
recommended body weight for their height according to
the Metropolitan Life Insurance Tables [55]. Lachish
et al. [58] defined inclusion criteria for control women
on the basis of weight status falling within 85 – 115% of
ideal body weight according to the Metropolitan Life In-
surance [55] criteria but did not report specific weight
data for the control group. All eleven studies reporting
on longitudinal data indicated a significant increase in
BMI during the course of treatment, with discharge BMI
ranging from 16.53 [48] to 20.4 [59].
Re-feeding protocol and additional treatment components
Seven studies provided a description of refeeding proto-
col applied for weight restoration. Of those seven, only
two studies [44,47] provided a description in terms of
daily caloric intake. Castro-Fornieles et al. [53] initiated
participants on meal plans of 1,500 kcal/day that in-
creased to 2500 kcal/day by the end of their admission.
Perez et al. [48] described that daily caloric intake in-
creased from less than 1200 kcal/day at admission to
greater than 1800 kcal/day at discharge; however, these
authors did not provide specification of procedure for
increased intake. The remaining five studies provided
brief and often vague descriptions of individualized meal
plans designed for nutritional rehabilitation.
Treatment duration and measurement time points
Treatment duration varied according to the model of
intervention and adopted definitions of recovery. Specific
discharge criteria were largely not reported; however, all
studies utilizing an inpatient population indicated a pre-
dominant goal of weight restoration. Castro-Fornieles
et al. [53] stipulated that both weight recovery and
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discharge, while Morgan et al. [59] indicated that individ-
uals must reach a mean matched population weight
(MMPW) prior to discharge. Four studies reported spe-
cific data for average treatment duration, with length of
hospitalization ranging from 29.8 days [53] to 4.9 months
[54]. Treatment duration for four additional studies could
be discerned from descriptions of treatment components.
Sala et al. [60] reported a prescriptive treatment length of
3 months based on four phases of treatment. Ricca et al.
[52] reported a 40-week treatment protocol. While Green
et al. [47] and Perez et al. [48] indicated total specific
measurement periods, 12 weeks and 14 weeks (±2) re-
spectively; it was unclear whether this represented the full
treatment duration. Two studies [46,59] did not report on
treatment duration.
In terms of measurement time points, all eight studies
utilizing inpatient populations only, reported outcomes
at least in relation to admission and discharge. There
was variability, however, in terms of allowed lapsed time
in relation to these treatment qualifiers. For instance,
Morgan et al. [59] reported a mean lag time of 18.5 days
(SD = 3.89) between admission and recruitment into the
study as a result of hospital protocol designed to prevent
research impediment on assessment process. Mattar
et al. [56] and Lachish et al. [58] collected data within
one week of admission, whilst Gauthier et al. [54] allowed
for measurement within two weeks of admission. Dahlgren
et al. [46] reported a mean lapse between treatment ad-
mission and baseline measurement of 36 days for their in-
patient population and 13 months for their outpatient
population.
In addition to baseline and discharge measures, four
studies included measurements at multiple time-points.
Brambilla et al. [51] and Morgan et al. [59] reported
monthly measurements throughout treatment, while
Green et al. [47] included an additional measurement
time-point one week after admission. Sala et al. [60] re-
ported measurements at each defined phase of treat-
ment. Four studies reported follow-up periods that
ranged from 9 months post-discharge [53] to 12 years
[56], however, for the purposes of the current systematic
review these assessments were not included. Pollice
et al. [45] used a cross-sectional study design and as
such only have one measurement time-point.
Medication
Ten studies accounted for the use of psychopharmacology,
while two studies [46,47] did not provide any information.
Of those studies reporting psychopharmacological data,
six studies reported on antidepressant medication with
use at admission ranging from 0 [58] to 51.2% [52]. Perez
et al. [48] accounted for use of antidepressant and anxio-
lytic medication with 56.25% of their inpatient populationreportedly on medication. Ricca et al. [52] excluded partic-
ipants if they were currently using any other psychoactive
medication, other than of anti-depressant medication.
Two studies reported percentage of participants on anti-
depressant medication at admission and discharge [54,58],
with both studies reporting a relative increase in medica-
tion use during hospitalization. Importantly, with the ex-
ception of one study [51], which was designed to assess
the relative impact of two antidepressant medications
(nortriptyline vs. fluoxetine), where medication status was
reported use of antidepressant medication was not signifi-
cantly related to outcome. Three studies [45,59,60] stipu-
lated that participants did not receive any psychotropic
medication prior to or during the study period.
Anxiety measures
Anxiety symptomatology was measured using a number
of different validated self-report questionnaires. The ma-
jority of studies only included one measure of anxiety;
however, two studies [45,56] used two measures of anx-
iety. Seven studies used the State Trait Anxiety Index
(STAI) [61], which is a widely used self-report instru-
ment that yields separate scores for state and trait anx-
iety experiences. One study [53] utilized a version of the
STAI that had been adapted for child and adolescent
populations (STAI-C) [62]. The well-validated Hamilton
Rating Scale for Anxiety (HARS) [63] was used by five
studies to measure behavioral and somatic symptoms as-
sociated with anxiety in the previous week. Perez et al.
[48] used the Screen for Child Anxiety-Related Emotional
Disorders (SCARED) [64], which is a self-report instru-
ment designed to screen for the presence of anxiety in
child and adolescent populations aged 9 – 18 years.
Change in anxiety symptomology
Seven studies reported a significant change in anxiety
symptomology, such that anxiety symptomology seemed
to recede during the course of treatment. Three of these
studies did not include statistical figures related to this
finding. Pollice et al. [45] in the only cross-sectional
study found that, whilst anxiety ratings were highest in
underweight anorexia nervosa patients, short-term and
long-term recovered patients with AN demonstrated
somewhat reduced levels of anxiety; however, these were
still elevated when compared to healthy controls. In con-
trast to these significant findings, the remaining five stud-
ies found no evidence of a significant change in anxiety
symptomology during the course of weight restoration.
Relationship between weight status and anxiety
symptomology
All five studies assessing the relationship between weight
status and anxiety symptomology failed to find a signifi-
cant relationship. That is, despite significant changes in
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mology, these two factors were not associated.
Evaluation of study quality
Quality ratings for individual studies are detailed in
Table 3. Quality scores ranged from 7 to 12, with an
average quality rating of 11.42 out of a possible 15. In
terms of subscale indices, scores for reporting quality
ranged from 5 to 7 (M = 6.41/7), for external validity
ranged from 0 to 3 (M = 1.67/3) and for internal validity
ranged from 2 to 3 (M = 2.25/4). Only one study [48]
provided a power calculation. Higher scores represent
greater methodological rigour, thus, these results indi-
cate that studies were scoring better for the reporting
and internal validity subscales than for the external val-
idity subscale.
Discussion
This systematic review aimed to critically evaluate exist-
ing literature regarding anxiety symptomology in rela-
tion to weight restoration in populations with AN.
Despite increasing evidence implicating the need to
understand anxiety within AN populations [41] and the
way in which anxiety may contribute to the maintenance
of symptoms in patients with AN [40], research remains
limited. Twelve studies, published between 1995 and
2014, fulfilled the criteria for review. Results regarding
change in anxiety symptoms during hospitalization for
weight restoration were inconsistent across studies, with
some studies reporting a decrease in anxiety and a simi-
lar portion reporting null findings. Evidence explicitly
examining the relationship between weight status and
anxiety symptomology was relatively sparse; overall it in-
dicated a non-significant association.
Summary of findings
Six studies reported a significant change in anxiety, such
that anxiety symptoms decreased over the course of
treatment. Interestingly, only two of these studies [51,60]
indicated that they had employed some form of psycho-
logical intervention, seemingly suggesting that anxiety
symptoms recede during treatment aimed at weight res-
toration despite not being directly targeted. These find-
ings are consistent with neurobiological models that
suggest that psychopathology can be confounded by
malnutrition associated with starvation in populations
with AN [22]. Notably, the majority of those studies
reporting a reduction in anxiety indicated that despite
the significant decrease, anxiety symptomology did not
resolve entirely, remaining at levels above those expected
for non-clinical populations. Inconsistent to the above-
mentioned studies, an equivalent number of studies in-
cluded in this review did not find a significant change in
anxiety symptoms over the course of hospitalization.Taken together, these finding seems to support sugges-
tions for the persistence of symptomology despite weight
normalization [24,25]. Alternatively, the apparent lack of
reduction in anxiety may in fact relate to a putative in-
crease in anxiety associated with weight gain in a popu-
lation diagnostically defined as having a fear of gaining
weight [2]. There is clearly a need for further research to
better understand this phenomenon.
All five studies assessing the relationship between
weight status and anxiety symptomology did not find a
significant association between these two variables. Im-
portantly, all of these studies reported improvement in
BMI and, with the exception of one study [52], an im-
provement in anxiety symptomology. While BMI change
did not always reflect an achievement of normative
weight levels, leaving the possibility for further improve-
ment and significant findings once weight normalization
is achieved, it seems unlikely that these null findings are
attributable to non-meaningful weight change. On the
basis of their null findings, Sala et al. [60] concluded that
extremely elevated baseline anxiety pathology can reduce
to moderate levels but may otherwise persist in AN pop-
ulations. Mattar et al. [56] concluded that it was unclear
which components of anxiety were related specifically to
malnutrition and which components may reflect con-
comitant anxiety for the individual, independent of mal-
nutrition. Gauthier et al. [54] extended this explanation
by suggesting that anxiety symptoms linked to malnutri-
tion recede but that symptoms independent from the
nutritional state may persist.
The aforementioned suggestions are consistent with
research indicating that weight restoration does not auto-
matically result in the resolution of anxiety and core psy-
chological difficulties in patients with AN [26-28]. Given
that anxiety may be a negative prognostic factor for recov-
ery [31,39] and that long-term treatment outcomes remain
poor [5], future research explicitly examining the temporal
relationship of anxiety and the treatment of individuals
with AN may delineate these propositions and assist in de-
veloping an understanding of psychological factors that
contribute to the pathogenesis and maintenance of the
disorder. The consideration of comorbid anxiety disorders
and resultant anxiety symptomology as independent from
eating disorder psychopathology may additionally extend
this understanding. Notably, only two of the included
studies [52,58] explicitly measured comorbid anxiety dis-
orders. Despite the evident utility of research in this area,
only a handful of studies have been conducted.
Given the scarcity of research within the area, inclu-
sion criteria concerning methodological design were
kept broad for this systematic review. While this allows
for a wide-ranging assessment of all available literature,
it is also a limitation of the current study. The heterogeneity
of included studies may explain the lack of consistent
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Treatment periods were highly variable, ranging from
29.8 days to 4.9 months. While this reflects observations
across clinical settings [65], it may limit meaningful com-
parisons. Additionally, treatment approaches varied mark-
edly. Some studies utilized additional behavioural and
psychological interventions, whilst others did not indicate
any specialist intervention beyond nutritional rehabilita-
tion. Nevertheless, there is no empirical evidence implicat-
ing the use of any one-treatment setting (i.e., inpatient,
outpatient, or day program) over the other [66,67]. Fur-
thermore, sample characteristics (e.g., participant age,
treatment setting) varied across studies. No meaningful
categorization of these variables seemed applicable in the
current study; however, future research may want to fur-
ther classify these factors.
A number of methodological strengths of the available
literature should be accounted for. These include the
use of appropriate criteria and health-professional inter-
views to enable a clinical diagnosis of AN, largely valid
and reliable methods of data collection and recruitment,
objective measurements of BMI, and the use of widely
used, validated and reliable measures to assess anxiety.
Furthermore, in general, quality ratings across all studies
were moderate. Mean scores for the internal validity
subscale of the Quality Index, in particular, suggest that
studies were adequate in producing internally valid re-
sults. Mean scores for the external validity subscale of
the Quality Index, however, imply the need for caution
when generalizing results. Patients across studies were
recruited predominantly from secondary and tertiary re-
ferral services (i.e., inpatient and outpatient services).
Whilst some studies included patients with sub-clinical
symptomology, findings cannot be generalized to non-
treatment seeking populations.
Despite these relative strengths, there are a number of
limitations evident in the reviewed literature. Poor treat-
ment outcome in AN is invariably associated with illness
chronicity and increased duration of symptology prior to
treatment intervention [5]. While the majority of studies
reported on these variables at baseline and/or included
exclusion criteria in an attempt to account for these var-
iables, they were largely unaccounted for in statistical
analyses. Furthermore, while the majority of the studies
accounted for the concurrent use of antidepressant
medication, other psychotropic medications were either
unaccounted for or participants were excluded on the
basis of their use. Evidence around the efficacy of these
psychopharmacological interventions is sparse and
largely inconclusive [68,69]. Nevertheless, atypical anti-
psychotic medication is increasingly used in the routine
treatment of AN patients [70] as a result of models pur-
porting the utility of the desirable side effect of weight
gain as well as their presumed effectiveness in targetinganxiety symptomology. Thus, it seems pertinent to rigor-
ously account for these psychopharmacological interven-
tions in studies designed to assess weight restoration
and anxiety symptomology in AN populations. Notably,
some of the studies included in the current review mea-
sured anxiety as a secondary outcome and as such did
not formulate study aims around the question prescribed
in the current systematic review.
Limited information about specific nutritional treat-
ment and caloric intake was provided by included studies.
At present, there are no clear recommended protocols for
ideal initial doses of nutrition [9,71]. However, emerging
research suggests that traditional refeeding programs, de-
signed to prevent the onset of refeeding syndrome, may
be too conservative [9]. As such, more aggressive ap-
proaches to weight restoration (in the context of intensive
metabolic monitoring) are emerging due to their propen-
sity to promote more efficient weight gain, reduction in
length of hospital stays and effective minimization of the
financial burden of inpatient care, without compromising
physiological well-being [71-73]. While there is some sug-
gestion that the rate of weight restoration during inpatient
treatment can be a significant predictor of short-term clin-
ical outcomes [74], research regarding the psychological
tolerability of rapid-refeeding protocols is deficient. Stud-
ies assessing the psychological impact of weight restor-
ation should invariably provide a detailed description and
analysis of the applied refeeding protocols to provide
clarification.
Conclusions
Taken together, the results of the current review high-
light marked inconsistencies in evidence regarding
change in anxiety symptoms during treatment. These
findings may be limited by numerous methodological
shortcomings, including inconsistencies in regards to in-
terventions and length of treatment, poor temporal as-
sessment of weight gain, as well as lack of control over
significant confounding variables (e.g., concurrent psy-
chopharmacological intervention, history and/or course
of illness, comorbid psychiatric diagnoses). The meth-
odological shortcomings render it almost impossible to
draw meaningful conclusions. Developing an under-
standing of additional factors that contribute to poor
weight normalization and conceptualizations of factors
that contribute independently to the maintenance of anor-
ectic symptoms is necessitated. Additional research into
alternate psychological factors such as co-morbid depres-
sion [75] or motivational factors [76] may be useful.
In regards to the relationship between anxiety symp-
toms and weight restoration, the results of the current re-
view do not support a significant association. In line with
this finding, evidence points towards the insufficiency of
solely targeting weight restoration for long-term recovery.
Kezelman et al. Journal of Eating Disorders  (2015) 3:7 Page 13 of 15While research affirms the importance and obligatory
targeting of weight restoration in the recovery of AN
[25], there are increasing suggestions that marked gaps
in the relative pace of physical and psychological recov-
ery [77] may hinder overall progress and attainment of
desirable clinical outcomes. Furthermore, Strober and
Johnson [78] suggested that there is no evidence – clin-
ical or empirical – to indicate that normal weight is a
necessary prerequisite for initiating meaningful psycho-
therapeutic interventions, which may facilitate weight
change. There is a current lack of empirical data, thus
rigorous research that directly assesses these proposi-
tions is urgently needed.
Appendix 1
Quality Index by (Ferro and Speechley [44]; amended
from Downs and Black [42]).
Reporting
1. Is the hypothesis/objective of the study clearly
described?
2. Are the main outcomes to be measured clearly de-
scribed in the Introduction/Method section?
3. Are the characteristics of the patients included in
the study clearly described?
4. Are the main findings of the study clearly described?
5. Does the study provide estimates of the random
variability in the data for the main outcome?
6. Have actual probability values been reported for the
main outcomes except where the probability value
is less than 0.001?
7. Is the response rate clearly described?
External Validity
8. Were the patients asked to participate in the study
representative of the entire population from which
they were recruited?
9. Were patients who were prepared to participate rep-
resentative of the entire population from which they
were recruited?
10. Were the staff, places and facilities where the pa-
tients were studied, representative of the treatment
the majority of patients receive?
Internal Validity (Bias and confounding)
11. If any of the results of the study were based on
“data dredging”, was this made clear?
12. Were the statistical tests used to assess the main
outcomes appropriate?
13. Were the main outcome measures used valid and
reliable?
14. Was there adequate adjustment for confounding in
the analyses from which the main results were
drawn?Power
15. Did the study provide a sample size or power calcu-
lation to detect important effects where the prob-
ability value for a difference being due to change is
less than 0.05?
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